Cargando…
Drug-Drug Interaction Assessment and Identification in the Primary Care Setting
BACKGROUND: Drug-drug interactions (DDIs) are ubiquitous, harmful and a leading cause of morbidity and mortality. With an aging population, growth in polypharmacy, widespread use of supplements, and the rising opioid abuse epidemic, primary care physicians (PCPs) are increasingly challenged with ide...
Autores principales: | Peabody, John, Acelajado, Maria Czarina, Robert, Tim, Hild, Cheryl, Schrecker, Joshua, Paculdo, David, Tran, Mary, Jeter, Elaine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188027/ https://www.ncbi.nlm.nih.gov/pubmed/30344815 http://dx.doi.org/10.14740/jocmr3557w |
Ejemplares similares
-
Clinical Utility of Definitive Drug–Drug Interaction Testing in Primary Care
por: Peabody, John, et al.
Publicado: (2018) -
Randomized Trial to Improve Primary Care Patient Management and Patient Outcomes Using a Drug–Drug Interaction Test: Confirmation of the DECART Simulated Patient Clinical Utility Trial Results
por: Peabody, John, et al.
Publicado: (2021) -
Finding the clinical utility of 1,5-anhydroglucitol among primary care practitioners
por: Peabody, John, et al.
Publicado: (2020) -
Clinical Variation in the Treatment Practices for Medication Nonadherence, Drug–Drug Interactions, and Recognition of Disease Progression in Patients with Chronic Cardiometabolic Diseases: A Cross-Sectional Patient Simulation Study among Primary Care Physicians
por: Valdenor, Czarlota, et al.
Publicado: (2022) -
Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
por: Peabody, John W, et al.
Publicado: (2023)